Abstract
A large number of therapeutic roles have been proposed for σ1 receptors but the involvement of σ1 receptor in non-acute pain had not been well explored up to now. σ1 receptor knock-out mice became available offering us the possibility to study the role of σ1 receptor in nociception, particularly in models where central sensitization processes play a significant role. Given the attractive therapeutic potential, we have developed a chemical program aimed at the discovery of novel and selective σ1 ligands. Herein we discuss the rational basis of this approach and report preliminary pharmacological results of several chemical series and aspects of their structure-activity relationship on σ1 receptor. Functional data in pain models are presented mainly on one series that provide evidence to consider selective σ1 receptor antagonists an innovative and alternative approach for treating neuropathic pain.
Keywords: Neuropathic pain, analgesia, sigma-1 antagonists, sigma-1 knock-out, central sensitization
Central Nervous System Agents in Medicinal Chemistry
Title: Selective Sigma-1 (σ1) Receptor Antagonists: Emerging Target for the Treatment of Neuropathic Pain
Volume: 9 Issue: 3
Author(s): Jose Luis Diaz, Daniel Zamanillo, Jordi Corbera, Jose Manuel Baeyens, Rafael Maldonado, Miquel Angel Pericàs, Jose Miguel Vela and Antoni Torrens
Affiliation:
Keywords: Neuropathic pain, analgesia, sigma-1 antagonists, sigma-1 knock-out, central sensitization
Abstract: A large number of therapeutic roles have been proposed for σ1 receptors but the involvement of σ1 receptor in non-acute pain had not been well explored up to now. σ1 receptor knock-out mice became available offering us the possibility to study the role of σ1 receptor in nociception, particularly in models where central sensitization processes play a significant role. Given the attractive therapeutic potential, we have developed a chemical program aimed at the discovery of novel and selective σ1 ligands. Herein we discuss the rational basis of this approach and report preliminary pharmacological results of several chemical series and aspects of their structure-activity relationship on σ1 receptor. Functional data in pain models are presented mainly on one series that provide evidence to consider selective σ1 receptor antagonists an innovative and alternative approach for treating neuropathic pain.
Export Options
About this article
Cite this article as:
Diaz Luis Jose, Zamanillo Daniel, Corbera Jordi, Baeyens Manuel Jose, Maldonado Rafael, Pericàs Angel Miquel, Vela Miguel Jose and Torrens Antoni, Selective Sigma-1 (σ1) Receptor Antagonists: Emerging Target for the Treatment of Neuropathic Pain, Central Nervous System Agents in Medicinal Chemistry 2009; 9 (3) . https://dx.doi.org/10.2174/1871524910909030172
DOI https://dx.doi.org/10.2174/1871524910909030172 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insulin-Like Growth Factor-1 and its Derivatives: Potential Pharmaceutical Application for Ischemic Brain Injury
Recent Patents on CNS Drug Discovery (Discontinued) Galanin: A Biologically Active Peptide
Current Drug Targets - CNS & Neurological Disorders Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives
Current Pharmaceutical Design Bowman-Birk Inhibitors from Legumes and Human Gastrointestinal Health: Current Status and Perspectives
Current Protein & Peptide Science Androgen Receptor in Human Health: A Potential Therapeutic Target
Current Drug Targets Endocannabinoid System: Emerging Role from Neurodevelopment to Neurodegeneration
Mini-Reviews in Medicinal Chemistry Neuroprotective Actions of Flavones and Flavonols: Mechanisms and Relationship to Flavonoid Structural Features
Central Nervous System Agents in Medicinal Chemistry Effects of Cannabis on Impulsivity: A Systematic Review of Neuroimaging Findings
Current Pharmaceutical Design Organic Synthesis Using Environmentally Benign Acid Catalysis
Current Organic Synthesis Adeno-Associated Viral Vectors for Clinical Gene Transfer Studies
Current Gene Therapy Microvascular Endothelial Dysfunction in Obesity and Hypertension
Current Pharmaceutical Design Design, Synthesis and Characterization of Novel Urolithin Derivatives as Cholinesterase Inhibitor Agents
Letters in Drug Design & Discovery Chemoprevention of Colorectal Cancer: Progress or Pipedream?
Current Cancer Therapy Reviews Methods for Quantitation and Clustering of Gene Expression Data
Current Genomics A Structural Approach into Human Tryptophan Hydroxylase and its Implications for the Regulation of Serotonin Biosynthesis
Current Medicinal Chemistry Actions of Alcohol in Brain: Genetics, Metabolomics, GABA Receptors, Proteomics and Glutamate Transporter GLAST/EAAT1
Current Molecular Pharmacology Overcoming Treatment Barriers in Adolescent Psychiatry
Adolescent Psychiatry Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury
Current Medicinal Chemistry Obstructive Sleep Apnea and Autoimmune Rheumatic Disease: Is there Any Link?
Inflammation & Allergy - Drug Targets (Discontinued) Transglutaminases - Possible Drug Targets in Human Diseases
Current Drug Targets - CNS & Neurological Disorders